{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:12:17Z","timestamp":1777921937093,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["LGBT Health"],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:p>Sexually and gender diverse (SGD) populations experience an increased prevalence and severity of posttraumatic stress disorder (PTSD) compared with the general population. Minority stress theory contextualizes this increased disease burden by outlining how stigma and discrimination (e.g., homophobia and transphobia) contribute to worse mental health outcomes. The standard-of-care pharmacotherapy for PTSD is associated with significant treatment resistance. 3,4-Methylenedioxymethamphetamine (MDMA)\u2013assisted psychotherapy (MDMA-AP) has emerged as an investigational treatment for PTSD but has lacked consideration for SGD populations. This article explores next steps in clinical trial design and implementation for the study of MDMA-AP with SGD populations who have PTSD.<\/jats:p>","DOI":"10.1089\/lgbt.2024.0103","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T09:19:02Z","timestamp":1724059142000},"page":"577-582","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Including Sexually and Gender Diverse Populations in 3,4-Methylenedioxymethamphetamine\u2013Assisted Psychotherapy Trial Research"],"prefix":"10.1177","volume":"11","author":[{"given":"Ziad","family":"Saade","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brady D.","family":"Hanshaw","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6624-8354","authenticated-orcid":false,"given":"Alex S.","family":"Keuroghlian","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"The Fenway Institute, Fenway Health, Boston, Massachusetts, USA."},{"name":"Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/jts.21848"},{"key":"e_1_3_4_3_2","unstructured":"Clark-Shoeb EB. Lykos Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for MDMA-Assisted Therapy for PTSD. Lykos Therapeutics: San Jose CA; 2024. Available from: https:\/\/news.lykospbc.com\/2024-02-09-Lykos-Therapeutics-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-MDMA-Assisted-Therapy-for-PTSD [Last accessed: July17 2024]."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02565-4"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","unstructured":"Reardon S. MDMA therapy for PTSD rejected by FDA panel. Nature: New York NY; 2024. Available from: https:\/\/www.nature.com\/articles\/d41586-024-01622-3 [Last accessed: July11 2024].","DOI":"10.1038\/d41586-024-01622-3"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796023000586"},{"key":"e_1_3_4_7_2","volume-title":"Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups","author":"National Academies of Sciences","year":"2022","unstructured":"National Academies of Sciences. Engineering, and Medicine; Policy and Global Affairs; Committee on Women in Science, Engineering, And Medicine; Committee on improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research. In: Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. (Bibbins-Domingo K, , Helman A. eds.). National Academies Press: Washington, DC; 2022."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40501-020-00204-0"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/lgbt.2015.0058"},{"key":"e_1_3_4_10_2","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th Ed).. American Psychiatric Association Publishing: Washington DC; 2013. Available from: https:\/\/psychiatryonline.org\/doi\/book\/10.1176\/appi.books.9780890425596 [Last accessed: July11 2024]."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2009.168971"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1772.18.01995-7"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/10926771.2013.785455"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1037\/trm0000104"},{"key":"e_1_3_4_15_2","article-title":"Recognizing the impact of racism-based traumatic stress on youth: Implications for research and clinical practice","author":"Kahhale I","year":"2024","unstructured":"Kahhale I, , Farrise K, , Das A, et al. Recognizing the impact of racism-based traumatic stress on youth: Implications for research and clinical practice. J Am Acad Child Adolesc Psychiatry, 2024; doi: 10.1016\/j.jaac.2024.03.022","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.129.5.674"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1037\/a0016441"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1037\/a0020487"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.932605"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1891\/LGBTQ-2021-0013"},{"key":"e_1_3_4_21_2","volume-title":"Measuring Sex, Gender Identity, and Sexual Orientation","author":"National Academies of Sciences","year":"2022","unstructured":"National Academies of Sciences, Engineering, and Medicine; Division of Behavioral and Social Sciences and Education; Committee on National Statistics; Committee on Measuring Sex, Gender Identity, and Sexual Orientation. (Becker T, Chin M, Bates N. eds.). Measuring Sex, Gender Identity, and Sexual Orientation. National Academies Press: Washington, DC; 2022."},{"key":"e_1_3_4_22_2","unstructured":"Fenway Health. Ready Set Go! Guidelines and Tips for Collecting Patient Data on Sexual Orientation and Gender Identity (SOGI). Boston MA; 2022. Available from: https:\/\/www.lgbtqiahealtheducation.org\/publication\/ready-set-go-a-guide-for-collecting-data-on-sexual-orientation-and-gender-identity-2022-update\/ [Last accessed: July11 2024]."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/19419899.2022.2106147"},{"issue":"1","key":"e_1_3_4_24_2","first-page":"64","article-title":"The impact of minority stress and gender identity on PTSD outcomes in sexual minority survivors of interpersonal trauma","volume":"12","author":"Solomon DT","year":"2019","unstructured":"Solomon DT, , Combs EM, , Allen K, et al. The impact of minority stress and gender identity on PTSD outcomes in sexual minority survivors of interpersonal trauma. Psychol Sex, 2019; 12(1\u20132):64\u201378; doi: 10.1080\/19419899.2019.1690033","journal-title":"Psychol Sex"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12144-019-00206-z"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1037\/tra0001440"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2020.43"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/0748175612449743"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1037\/sgd0000081"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-024-00252-y"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1995"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-015-0480-x"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2012.06.006"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145713001405"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.991753"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.138"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/scan\/nst161"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1037\/sah0000143"},{"key":"e_1_3_4_39_2","unstructured":"Mithoefer M Mithoefer A Jerome L et al. A Manual for Adherence Ratings of MDMA-Assisted Therapy for Treatment of Posttraumatic Stress Disorder. Multidisciplinary Association for Psychedelic Studies: San Jose CA; 2021. Available from: https:\/\/mapscontent.s3.us-west-1.amazonaws.com\/research-archive\/Adherence+Ratings+Manual+Version+6_3AUG2021.pdf [Last accessed: May31 2024]."},{"key":"e_1_3_4_40_2","volume-title":"LSD Psychotherapy: The Healing Potential of Psychedelic Medicine","author":"Grof S","year":"2008","unstructured":"Grof S. LSD Psychotherapy: The Healing Potential of Psychedelic Medicine. Multidisciplinary Association for Psychedelic Studies: San Jose, CA; 2008."},{"key":"e_1_3_4_41_2","unstructured":"Christ C Bartlett A Manoni-Millar S et al. The Future is Queer: Imagining Queer-Affirming MDMA-Assisted Therapy. Multidisciplinary Association for Psychedelic Studies: San Jose CA; 2021. Available from: https:\/\/maps.org\/news\/bulletin\/the-future-is-queer-imagining-queer-affirming-mdma-assisted-therapy\/ [Last accessed: June17 2024]."},{"key":"e_1_3_4_42_2","unstructured":"Food and Drug Administration Advisory Committee. Updated Meeting Time and Public Participation Information: June 4 2024: Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting Announcement. U.S. Food and Drug Administration: Silver Spring MD; 2024. Available from: https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/updated-meeting-time-and-public-participation-information-june-4-2024-meeting-psychopharmacologic [Last accessed: July17 2024]."}],"container-title":["LGBT Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/lgbt.2024.0103","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/lgbt.2024.0103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/lgbt.2024.0103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:06:43Z","timestamp":1777666003000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/lgbt.2024.0103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12,1]]}},"alternative-id":["10.1089\/lgbt.2024.0103"],"URL":"https:\/\/doi.org\/10.1089\/lgbt.2024.0103","relation":{},"ISSN":["2325-8292","2325-8306"],"issn-type":[{"value":"2325-8292","type":"print"},{"value":"2325-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}